NASDAQ: THAR
Tharimmune Inc Stock Ownership - Who owns Tharimmune?

Insider buying vs selling

Have Tharimmune Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Sireesh AppajosyulaChief Executive Officer2025-06-2060,806$1.48
$89.99kBuy
Sireesh AppajosyulaChief Executive Officer2025-06-20690$1.42
$979.80Buy
Gravitas Capital LPExecutive Chairman2025-06-20337,838$1.48
$500.00kBuy
Sanam ParikhDirector2025-06-201,000$1.45
$1.45kBuy
Sanam ParikhDirector2025-05-15770$1.30
$1.00kBuy
Randy MilbyCEO2024-12-194,600$2.12
$9.75kBuy

1 of 1

THAR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when THAR insiders and whales buy or sell their stock.

THAR Shareholders

What type of owners hold Tharimmune Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Highpoint Pharmaceuticals LLC2.77%972,222$2.29MInsider
Kufe LLC2.31%810,395$1.91MInsider
Vincent S. Lopriore2.09%732,424$1.73MInsider
Gravitas Capital LP2.09%732,424$1.73MInsider
Surender Kharbanda2.06%721,240$1.70MInsider
Blackrock Inc1.89%663,882$1.57MInstitution
Varinder Kaur1.86%653,059$1.54MInsider
Sandeep Laumas1.81%636,008$1.50MInsider
Leonard L. Mazur0.35%123,733$292.01kInsider
Gary S. Stetz0.29%101,351$239.19kInsider

1 of 3

THAR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
THAR2.30%15.90%Net Buying
CSBR1.92%98.08%Net BuyingNet Buying
ARTV53.73%46.27%Net SellingNet Selling
PRLD43.21%52.21%Net BuyingNet Selling
KZIA0.02%2.75%

Tharimmune Stock Ownership FAQ

Who owns Tharimmune?

Tharimmune (NASDAQ: THAR) is owned by 2.30% institutional shareholders, 15.90% Tharimmune insiders, and 81.80% retail investors. Highpoint Pharmaceuticals LLC is the largest individual Tharimmune shareholder, owning 972,222.00 shares representing 2.77% of the company. Highpoint Pharmaceuticals LLC's Tharimmune shares are currently valued at $2.30M.

If you're new to stock investing, here's how to buy Tharimmune stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.